VULGA XR 55MG 30TAB

Indications

Approved Uses

Inflammatory lesions of non-nodular moderate to severe acne vulgaris (XR formulation).

Off-Label Uses

Examples of off-label uses include rosacea, rheumatoid arthritis (as a DMARD adjunct in some settings), and certain skin/soft-tissue infections including community-acquired MRSA when susceptible.

Dosage & Administration

Dosing by Condition

Acne vulgaris (XR): approximately 1 mg/kg orally once daily for up to 12 weeks; the 55 mg strength corresponds to patients ~50-59 kg (typical weight-band dosing).

Initial Dose

55 mg once daily (for patients weighing 50-59 kg) for acne vulgaris using XR formulation

Maintenance Dose

55 mg once daily (weight-based, XR formulation for acne); 100 mg every 12 hours (immediate-release for infections)

Maximum Dose

For extended-release minocycline (e.g., 55 mg XR), the usual maximum is 1 mg/kg once daily (do not exceed 115 mg once daily for XR acne products); immediate-release regimens for infections may be higher per indication, but XR products are not intended to exceed the XR max.

Children's Dosage

Not approved for children under 12 years for XR formulation; immediate-release dosing for children ≥8 years: 4 mg/kg loading dose, then 2 mg/kg every 12 hours.

Dose Adjustment Notes

No routine dose titration for XR acne dosing; use caution in renal impairment-consider lowering total daily dose or extending the dosing interval in significant renal dysfunction; use caution with hepatic impairment and with prolonged therapy.

How to Take

Swallow the prolonged-release (XR) tablet whole with a full glass of water; do not crush, chew, or split. Take once daily at the same time each day. May be taken with or without food (food can reduce GI upset). Take while upright and remain upright for at least 30 minutes to reduce esophageal irritation.

Side Effects

Common Side Effects

Headache, dizziness/vertigo, nausea, vomiting, diarrhea, fatigue, pruritus/rash, and skin hyperpigmentation/discoloration; photosensitivity can occur.

Side Effect Frequency

Common (≥1%): dizziness/vertigo, headache, nausea; less common/rare: diarrhea, pruritus/rash, photosensitivity, skin/mucosal pigmentation; rare but serious: intracranial hypertension, hypersensitivity reactions (including SJS/TEN), drug-induced lupus/autoimmune hepatitis, and C. difficile-associated diarrhea

Safety & Warnings

Contraindications

Hypersensitivity to minocycline or other tetracyclines; pregnancy; breastfeeding; children <8 years (tooth discoloration/bone effects). Avoid concomitant systemic retinoids (e.g., isotretinoin) due to intracranial hypertension risk (generally treated as a contraindicated/avoid combination).

Warnings & Precautions

Warn about intracranial hypertension (headache/visual changes-stop and evaluate; avoid isotretinoin); photosensitivity (sun protection); permanent tooth discoloration/enamel hypoplasia (avoid <8 years and during pregnancy due to fetal tooth/bone effects); vestibular effects (dizziness/vertigo-caution driving); risk of autoimmune syndromes/hepatitis with prolonged use (monitor symptoms/LFTs); superinfection including C. difficile diarrhea; counsel on reduced oral contraceptive reliability and need for backup if concerned.

Age Restriction

Not approved under 12 years for acne vulgaris.

Driving Warning

Safe

Drug Interactions

Drug Interactions

Chelation reduces absorption with aluminum/magnesium/calcium antacids and iron/zinc (separate dosing); avoid systemic retinoids (isotretinoin) due to intracranial hypertension; may potentiate warfarin/anticoagulants (monitor INR); may reduce effectiveness of oral contraceptives (advise backup); may antagonize penicillins; avoid methoxyflurane (nephrotoxicity).

Interaction Severity

MAJOR: Oral retinoids (e.g., isotretinoin) due to additive risk of intracranial hypertension; methoxyflurane due to nephrotoxicity. MODERATE: Warfarin/anticoagulants (↑ anticoagulant effect-monitor INR), antacids/iron/calcium/magnesium/zinc (↓ absorption-separate dosing), penicillins (possible antagonism), oral contraceptives (possible reduced efficacy-advise backup if concerned).

Food Interaction

Can be taken with or without food; taking with food may reduce GI upset. Avoid coadministration with polyvalent cations (antacids or supplements containing aluminum, magnesium, calcium, iron, zinc) and separate by at least 2 hours (preferably 2-3 hours). Dairy has less impact than other tetracyclines but separation is still prudent if possible.

Alcohol Interaction

Safe

Special Populations

Pregnancy

Contraindicated

Breastfeeding

Contraindicated

Children

Not approved for children under 12 years for XR formulation; immediate-release dosing for children ≥8 years: 4 mg/kg loading dose, then 2 mg/kg every 12 hours.

Elderly

Standard adult dosing; use with caution due to increased risk of vestibular side effects and potential renal/hepatic impairment. Monitor renal and hepatic function.

Kidney Impairment

Reduce dose and/or extend dosing interval in renal impairment; use caution in severe renal dysfunction (risk of azotemia/acidosis), and avoid high total daily doses-XR has limited adjustment data so monitor closely if used.

Liver Impairment

No specific dose adjustment is defined; use with caution in hepatic impairment, avoid or use only with close monitoring in severe hepatic disease, and monitor for hepatotoxicity (LFTs/symptoms) especially with prolonged therapy.

Storage & Patient Advice

Storage Conditions

Store below 30°C (per SFDA verified API data); keep in original blister to protect from moisture/light

Missed Dose

Take the missed dose as soon as remembered; if it is close to the next scheduled dose, skip the missed dose and resume the regular schedule. Do not double doses.

Stopping the Medicine

Do not stop early for an infection-complete the prescribed course unless significant adverse effects occur; for acne/long-term use, discuss stopping with the prescriber and stop immediately if serious reactions occur (e.g., severe headache/visual changes, rash, hypersensitivity).

Overdose

Expected overdose effects include dizziness/vertigo, nausea/vomiting, and other GI upset; management is supportive (consider activated charcoal if recent ingestion), monitor vitals and hydration, and seek urgent medical care; hemodialysis is not effective for removal.

Patient Counseling

Swallow XR tablet whole with a full glass of water; do not crush/chew/split. Take once daily at the same time; with or without food (food may help nausea). Stay upright for at least 30 minutes after dosing. Separate from antacids/iron/calcium/magnesium/zinc by ≥2 hours (preferably 2-3 hours). Use sun protection (photosensitivity). May cause dizziness/vertigo-use caution driving. Seek care urgently for severe headache/vision changes (intracranial hypertension) or severe rash/hypersensitivity. Avoid in pregnancy; discuss breastfeeding and contraception considerations with the prescriber.

Monitoring Requirements

If prolonged therapy: periodic renal and hepatic function tests and CBC; monitor clinically for intracranial hypertension (severe headache/visual changes), hypersensitivity/serious rash, and signs of drug-induced lupus/autoimmune hepatitis (consider ANA/autoimmune workup if symptomatic).

Pharmacology

Mechanism of Action

Reversibly binds the bacterial 30S ribosomal subunit, inhibiting protein synthesis by blocking aminoacyl-tRNA attachment to the mRNA-ribosome complex.

Onset of Action

Antibacterial activity begins after absorption (within hours); for acne/rosacea, noticeable clinical improvement typically starts in ~2-4 weeks (full benefit may take 6-12 weeks).

Duration of Effect

Approximately 24 hours of antibacterial coverage per XR dose (once-daily); sustained clinical benefit requires continued daily therapy and is maintained only while treatment continues.

Half-Life

Approximately 11-24 hours

Bioavailability

Approximately 90-100% (high oral bioavailability)

Metabolism

Hepatic metabolism to minor metabolites (including 4-epiminocycline); not primarily CYP-mediated (no established primary CYP3A4 metabolism)

Excretion

Primarily non-renal (fecal/biliary) with a smaller renal component; only a minority is recovered unchanged in urine (commonly cited ~5-12%)

Protein Binding

Approximately 76%

Product Information

Available Dosage Forms

For this product: oral prolonged-release (XR) film-coated tablet, 55 mg (blister pack of 30).

Composition per Dose

Each extended-release film-coated tablet: 55 mg minocycline (as minocycline hydrochloride)

Generic Availability

No

OTC Alternatives

No OTC alternative for systemic treatment. Topical options like benzoyl peroxide or salicylic acid exist for acne.

Spectrum

Broad-spectrum

Antibiotic Class

Tetracycline

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.